The company has substantially advanced its progress of a novel therapy for cardiac amyloidosis, employing Attruby. Early trial results suggests significant benefits for patients diagnosed from the severe disease. This https://biotech067352.weblogco.com/42430522/firm-progresses-cardiac-amyloidosis-management-through-the-therapy